Subscribe To
CTABF / Canntab Therapeutics provides update on recent product delivery of its cannabinoid solutions to the Nova Scotia Liquor Corporation
Content Topics
Canntab
Therapeutics
Provides
Update
Recent
Product
Delivery
Cannabinoid
Solutions
Scotia
Liquor
Corporation
Stock
CTABF
CTABF News
By Proactive Investors
November 22, 2022
Canntab Therapeutics seeks to move manufacturing process as Markham lease expires
Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) has provided an update on several matters impacting the company, including plans to move its manufact more_horizontal
By Proactive Investors
August 22, 2022
Canntab Therapeutics provides update on recent product delivery of its cannabinoid solutions to the Nova Scotia Liquor Corporation
Canntab Therapeutics Limited has provided an update on the recent product delivery of its unique pharmaceutical cannabinoid solutions to the Nova Scot more_horizontal
By Proactive Investors
April 13, 2022
Canntab Therapeutics appoints Hamish Sutherland as strategic business consultant
Canntab Therapeutics Ltd said it has appointed Hamish Sutherland as a strategic business consultant to develop additional sales and distribution chan more_horizontal
By Proactive Investors
March 23, 2022
Canntab Therapeutics inks affiliate deal with independent pharmacy owners in Ontario
Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) announced that it has entered into an affiliate agreement with OnPharm-United, a 600-plus network of more_horizontal
By Proactive Investors
February 2, 2022
Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000
Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) said it has closed a non-brokered private placement of secured convertible debentures of the company, more_horizontal
By Proactive Investors
February 2, 2022
Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000
Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) said it has closed a non-brokered private placement of secured convertible debentures of the company, more_horizontal
By Proactive Investors
February 2, 2022
Canntab Therapeutics closes non-brokered private placement of secured convertible debentures for gross proceeds of $1,312,000
Canntab Therapeutics Ltd (CSE:PILL, OTCQB:CTABF) said it has closed a non-brokered private placement of secured convertible debentures of the company, more_horizontal